T De Baere et al Annals of oncology
(2020) VOLUME 31, SUPPLEMENT 3, S220, JULY 01
Featured product: LifePearl™ Drug Elutable Microspheres
Transarterial chemoembolization (TACE) is indicated for the treatment of hepatocellular carcinoma (HCC) not amenable to curative treatments in patients with preserved liver function. Level 1 evidence indicates that TACE prolongs survival in patients with well-compensated liver disease and BCLC-B stage HCC and BCLC 0-A not suitable for options with higher priority.
Objective:Drug eluting microspheres (DEM) loaded with anthracyclines is a variation of TACE that enables a sustained drug release. LifePearlTM microspheres is a novel DEM comprised of polyethylene-glycol with good safety profile and efficacy as reported in different studies. The purpose of this study was to assess the safety and efficacy of anthracycline-loaded LifePearl Microspheres for the treatment of patients with unresectable HCC in a pooled analysis of studies with available patient's level data from more than 500 patients.MethodsThe authors pooled patient-level data from 5 single-arm studies (3 retrospective and 2 prospective, including one pharmacokinetics study). Safety was assessed by close monitoring of adverse events according to CTCAE (v4.03). Tumour response was evaluated following hospital practice, according to mRECIST and RECIST1.1 and analyzed as best overall response (BOR) to account for differences in imaging follow up between studies. The Kaplan-Meier method was used to estimate event rates for time to event outcomes: progression-free survival (PFS), time to unTACEable progression (TTUP) and overall survival (OS).ResultsDe Baere et al pooled analysis (n=586) demonstrated :
Out of 586 patients, 72.1% were males, with mean age of 66.8±10.3years.
At baseline, patients were 85.5% Child-Pugh A, 13.5% B and 1.0% C. The mean number of HCC lesions was 2.1±1.5 and mean sum of tumour diameters was 49.3±32.9mm. BCLC stages 0, A, B and C were 13.6%, 43.4%, 41.1% and 1.9%, respectively. The mean alpha-fetoprotein level was 680.2±4,241.0 ng/ml with 18.8% patients having > 200ng/ml.
A mean of 1.9±1.0 procedures was performed per patient.
The median PFS was 11.7 [10.1; 13.0] months and TTUP was 16.4 [15.1; 19.2] months
Limitations: As this pooled analysis was not planned prior to conducting the individual studies, analysis limitations are related to differences in the actual recording of the variables, frequency, timing and type of imaging, follow-up period and sample size.
Conclusion De Baere et al concluded that the treatment of patients with unresectable HCC with LifePearl Microspheres loaded with doxorubicin or idarubicin showed good tolerance with acceptable toxicity and high tumour response rate that translated into promising PFS, TTUP and OS. Key TakeawayAccording to De Baere et al publication, the data from 586 patients treated for unresectable HCC with LifePearl microspheres loaded with doxorubicin or idarubicin showed:
Access to the full publication: https://www.annalsofoncology.org/article/S0923-7534(20)39322-4/fulltext
European Economic Area Indications for useLifePearl™ microspheres are indicated for embolization of blood vessels supplying primary hypervascular tumours or metastases in the liver. Note: LifePearl™ microspheres can be loaded with chemotherapeutic drugs. When used for drug loading, drug loading should be done under a physician's direction, choice and responsibility, based on type and dose of drug most beneficial to the patient. LifePearl™ microspheres are compatible with doxorubicin, epirubicin idarubicin and irinotecan. LifePearl™ microspheres can be drug loaded prior to embolization and then, as a secondary action, elute a local, controlled, and sustained dose to the targeted tumour sites after embolization. LifePearl™ microspheres are not available for sale in all countries. This information is provided only in respect to markets where this product is approved or cleared.This literature summary is not a systemic review. It is only an example of LifePearl microspheres related literatures.The use of the LifePearl™ devices in combination with drugs is not cleared or approved in the USA by the Food and Drug Administration. LifePearl™ microspheres are not approved in Canada. Please consult the indication of use with the IFU supplemented with the product.Please contact your Terumo local sales representative for more information. All brand names are trademarks or registered trademarks of TERUMO CORPORATION and their respective owners. Refer to Instructions for Use for Contraindications, Warnings and Precautions.
©2021 MicroVention Europe CE0297
ManufacturerMicroVention Europe30 bis, rue du Vieil Abreuvoir78100 Saint-Germain-en-Laye - FranceTel: +33(0)1 39 21 77 46DistributorTerumo Europe N.V.Interleuvenlaan 403001 Leuven BelgiumTel: +32 16 38 12 11
This is HCP only content
website and cannot be refused. Other cookies are only placed if you choose to do so. For further information, please read our cookies policy.
Essential cookies to ensure the website functions well.
Cookies to help us measure the general use of our website.
Cookies that save personal information while browsing.